The 12 most recent market catalysts affecting $CGEM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35
HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Cullinan Therapeutics (CGEM) and raised the price target from $30 to $35. This update signals continued co…
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
This 8-K filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Cullinan Therapeutics (CGEM) and maintained a $40 price target. This action signals con…
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 75
Cullinan Therapeutics shares are trading lower after the company outlined upcoming fourth-quarter data milestones across its autoimmune and oncology pipeline.
The negative market reaction to Cullinan Therapeutics' announcement of upcoming data milestones is counterintuitive and suggests that the market either expected more significant ne…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40
BTIG analyst Julian Harrison maintained a 'Buy' rating on Cullinan Therapeutics (CGEM) and raised the price target from $39 to $40. This action signals continued bullish sentiment …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 85
Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET
Cullinan Therapeutics (CGEM) has announced that its Phase 3 REZILIENT3 trial for zipalertinib, targeting EGFR exon 20 insertion mutation NSCLC, met its primary endpoint of progress…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 75
Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer
Cullinan Therapeutics (CGEM) announced that the interim analysis of its Phase 3 REZILIENT3 trial, evaluating zipalertinib for NSCLC, met its primary endpoint and has been selected …
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Robert Burns has reaffirmed a 'Buy' rating and a $30 price target for Cullinan Therapeutics (CGEM). This action signals c…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics (CGEM) announced that its zipalertinib combination therapy met the primary endpoint of progression-free survival in a Phase 3 trial for first-line NSCLC with …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42
Wedbush analyst Robert Driscoll maintained an 'Outperform' rating on Cullinan Therapeutics and raised the price target from $39 to $42. This action signals continued confidence in …
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 85
Reported Earlier, Cullinan Therapeutics And Taiho Partners Announce Phase 3 REZILIENT3 Trial Shows Clinically Meaningful PFS Improvement With Zipalertinib Plus Chemotherapy In EGFR Exon 20 Insertion NSCLC
The positive Phase 3 trial results for zipalertinib represent a major corporate catalyst for Cullinan Therapeutics and Taiho Oncology. Clinically meaningful PFS improvement in EGFR…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39
BTIG analyst Julian Harrison maintained a 'Buy' rating on Cullinan Therapeutics (CGEM) and raised the price target from $38 to $39. This action signals continued analyst confidence…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
Cullinan Therapeutics Announces Positive Feedback From FDA Following End-Of-Phase 1 Meeting For CLN-049, FLT3xCD3 T Cell Engager Being Evaluated In Patients With Acute Myeloid Leukemia
Cullinan Therapeutics announced positive feedback from the FDA following an End-of-Phase 1 meeting for its drug candidate CLN-049, which is being developed for acute myeloid leukem…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.